AstraZeneca PLC
AstraZeneca PLC Fundamental Analysis
AstraZeneca PLC (AZN) shows strong financial fundamentals with a PE ratio of 27.10, profit margin of 17.19%, and ROE of 22.27%. The company generates $60.5B in annual revenue with strong year-over-year growth of 10.95%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 70.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze AZN's fundamental strength across five key dimensions:
Efficiency Score
WeakAZN struggles to generate sufficient returns from assets.
Valuation Score
ModerateAZN shows balanced valuation metrics.
Growth Score
ExcellentAZN delivers strong and consistent growth momentum.
Financial Health Score
ModerateAZN shows balanced financial health with some risks.
Profitability Score
ExcellentAZN achieves industry-leading margins.
Key Financial Metrics
Is AZN Expensive or Cheap?
P/E Ratio
AZN trades at 27.10 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, AZN's PEG of 0.80 indicates potential undervaluation.
Price to Book
The market values AstraZeneca PLC at 5.95 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.48 times EBITDA. This signals the market has high growth expectations.
How Well Does AZN Make Money?
Net Profit Margin
For every $100 in sales, AstraZeneca PLC keeps $17.19 as profit after all expenses.
Operating Margin
Core operations generate 23.69 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $22.27 in profit for every $100 of shareholder equity.
ROA
AstraZeneca PLC generates $9.11 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
AstraZeneca PLC produces operating cash flow of $14.33B, showing steady but balanced cash generation.
Free Cash Flow
AstraZeneca PLC generates strong free cash flow of $9.12B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.88 in free cash annually.
FCF Yield
AZN converts 3.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.80
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.66
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.72
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How AZN Stacks Against Its Sector Peers
| Metric | AZN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.10 | 28.62 | Neutral |
| ROE | 22.27% | 783.00% | Weak |
| Net Margin | 17.19% | -48181.00% (disorted) | Strong |
| Debt/Equity | 0.72 | 0.39 | Weak (High Leverage) |
| Current Ratio | 0.91 | 4.12 | Weak Liquidity |
| ROA | 9.11% | -21914.00% (disorted) | Weak |
AZN outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews AstraZeneca PLC's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
69.87%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
155.30%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
157.08%
Industry Style: Defensive, Growth, Innovation
High Growth